Markets:

Overview

News

Currencies

International

Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

57.80 +7.97 (+15.99%)

Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Why Moderna (MRNA) Stock Is Trading Up Today

Today 16:00 EST

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 17.4% in the afternoon session after the company settled a long-running patent di...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Exploring the top movers within the S&P500 index during today's session. ↗

Today 15:05 EST

Via Chartmill

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

Today 14:18 EST

The news is likely to come as a relief to many investors, Citi told investors in a research note.

Via Stocktwits

Topics Intellectual Property

Discover which S&P500 stocks are making waves on Wednesday. ↗

Today 12:35 EST

Via Chartmill

2 High-Flying Stocks With More Upside to Buy and Hold ↗

Today 9:32 EST

It's not too late to get in on the action.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

Get insights into the top movers in the S&P500 index of Wednesday's pre-market session. ↗

Today 8:35 EST

Via Chartmill

MSTR, CRWD, MRNA, GTLB On Traders' Radar Today — Dow Futures Edge Higher As Investors Look Past Middle East Conflict ↗

Today 6:21 EST

Following warnings from Iran over the closure of the Strait of Hormuz, President Donald Trump announced that the U.S. would extend risk insurance for maritime trade through the strait.

Via Stocktwits

Topics ETFs Government Intellectual Property

These stocks are moving in today's after hours session ↗

March 03, 2026

Via Chartmill

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Via Stocktwits

Topics Intellectual Property

Exploring the top movers within the S&P500 index during today's session. ↗

March 03, 2026

Via Chartmill

Moderna Stock (MRNA): Is It a Buy Now? 7 Questions After the Crash ↗

March 02, 2026

Moderna stock has crashed 90% — but is the market mispricing what comes next? 7 key questions on MRNA's cancer vaccine, cash runway, and upside case.

Via InvestorPlace

The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines

February 27, 2026

As of today, February 27, 2026, the biotech sector is witnessing a dramatic reappraisal of one of its most storied pandemic-era players. Novavax (NASDAQ: NVAX) has surged 17.4% following the release of...

Via Finterra

Topics Economy

Moderna's Ups and Downs: Here's What You Need to Know Before Investing. ↗

February 25, 2026

The stock, after a few tough years, soared in the double-digits in January.

Via The Motley Fool

3 Reasons to Avoid MRNA and 1 Stock to Buy Instead

February 24, 2026

What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 99.8%, hitting $50.65. This was partly due to its solid quarterly results, and the run-up might have investors...

Via StockStory

Moderna Stock Is Trading Higher Today: What's Going On? ↗

February 23, 2026

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating.

Via Benzinga

Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear ↗

February 23, 2026

Moderna made a fortune with COVID vaccines, but revenue has since declined.

Via The Motley Fool

Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January. ↗

February 21, 2026

Laffont's new addition may represent an exciting recovery story.

Via The Motley Fool

Topics Artificial Intelligence

Friday's session: gap up and gap down stock in the S&P500 index ↗

February 20, 2026

Via Chartmill

Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions

February 20, 2026

Moderna’s fourth quarter results were received positively by the market, reflecting a combination of better-than-expected revenue and effective cost management. Management cited the successful U.S....

Via StockStory

Topics Earnings

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 19, 2026

Via Chartmill

3 Once-in-a-Decade Buying Opportunities ↗

February 18, 2026

Bargain-hunters should give these stocks a close look.

Via The Motley Fool

Topics Artificial Intelligence

Why Moderna (MRNA) Stock Is Trading Up Today

February 18, 2026

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.9% in the afternoon session after the U.S. Food and Drug Administration (FDA) reversed an earlier decision and agreed to review the...

Via StockStory

Topics Economy

These S&P500 stocks are moving in today's session ↗

February 18, 2026

Via Chartmill

Why Moderna Stock Just Popped ↗

February 18, 2026

So the FDA will consider Moderna's flu vaccine application after all. Does this make Moderna stock a buy?

Via The Motley Fool

Wednesday's session: gap up and gap down stock in the S&P500 index ↗

February 18, 2026

Via Chartmill

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review ↗

February 18, 2026

The FDA has now accepted the biologics license application for review, setting a Prescription Drug User Fee Act goal date of Aug. 5, 2026.

Via Stocktwits

What's going on in today's pre-market session: S&P500 movers ↗

February 18, 2026

Via Chartmill

3 Stocks Under $50 with Warning Signs

February 17, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.